Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
1 finding from 1 review
Symptoms of opioid withdrawal in the medium term · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
Naloxone + oxycodone prolonged release tablets showed no clear difference in symptoms of opioid withdrawalfin the medium termb compared with oxycodone prolonged‐released tablets (low certainty).
1 finding from 1 review
Serious adverse eventsg · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
It is very uncertain whether naloxone + oxycodone prolonged release tablets changes serious adverse eventsg compared with oxycodone prolonged‐released tablets (very low certainty).
1 finding from 1 review
Adverse events · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
Naloxone + oxycodone prolonged release tablets showed no clear difference in adverse events compared with oxycodone prolonged‐released tablets (low certainty).
1 finding from 1 review
Outcomes · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in quality of life1 St George's Respiratory Questionnaire (SGRQ); lower… compared with placebo (moderate certainty).
1 finding from 1 review
Severe exacerbations requiring hospitalisation over the study period · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists probably leads to lower severe exacerbations (hospitalisations) compared with placebo (moderate certainty).
1 finding from 1 review
Moderate exacerbations (course of antibiotics or oral steroids) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists probably leads to lower moderate exacerbations (course of antibiotics or oral steroids) compared with placebo (moderate certainty).
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in severe/moderate exacerbations (hospitalisation or course of… compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
1 finding from 1 review
Participants with one or more serious adverse event (non‐fatal) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in participants with one or more serious adverse event (non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in predose FEV1 (mL) compared with placebo (low certainty).
1 finding from 1 review
Live birth rate
Long‐acting FSH (all doses) probably leads to lower live birth rate ‐ Low dose (60 to 120 μg) compared with daily FSH (moderate certainty).
3 findings from 1 review
RR 0.7 [0.52, 0.93]
3 studies · 645 participants
Moderate
RR 1.03 [0.9, 1.18]
4 studies · 1685 participants
Moderate
RR 0.43 [0.12, 1.52]
1 study · 33 participants
Very low
OHSS ‐ Low dose (60 to 120 μg)
Long‐acting FSH (all doses) showed no clear difference in OHSS ‐ Low dose (60 to 120 μg) compared with daily FSH (moderate certainty).
1 finding from 1 review
OHSS ‐ Medium dose (150 to 180 μg)
Long‐acting FSH (all doses) showed no clear difference in OHSS ‐ Medium dose (150 to 180 μg) compared with daily FSH (low certainty).
1 finding from 1 review
OHSS ‐ High dose (240 μg)
It is very uncertain whether long‐acting FSH (all doses) changes OHSS ‐ High dose (240 μg) compared with daily FSH (very low certainty).
1 finding from 1 review
Live birth rate · patients with endometriosis prior to standard IVF/ICSI
It is very uncertain whether long‐term GnRH agonist therapy changes live birth rate compared with no additional therapy (very low certainty).
1 finding from 1 review
Complication rate · patients with endometriosis prior to standard IVF/ICSI
It is very uncertain whether long‐term GnRH agonist therapy changes complication rate compared with no additional therapy (very low certainty).
1 finding from 1 review
Clinical pregnancy rate · patients with endometriosis prior to standard IVF/ICSI
It is very uncertain whether long‐term GnRH agonist therapy changes clinical pregnancy rate compared with no additional therapy (very low certainty).
1 finding from 1 review